Identifying Hepatic Nuclear Factor 1α Mutations in Children and Young Adults With a Clinical Diagnosis of Type 1 Diabetes
- A. Paul Lambert, BA, MRCP1,
- Sian Ellard, PHD, MRCPath2,
- Lisa I.S. Allen, MSC2,
- Ian W. Gallen, MD, FRCP3,
- Kathleen M. Gillespie, PHD1,
- Polly J. Bingley, MD, FRCP1 and
- Andrew T. Hattersley, DM, FRCP2
- 1Department of Diabetes and Metabolism, Division of Medicine, University of Bristol, Bristol, U.K.
- 2Centre for Molecular Genetics, Peninsular Medical School, Exeter, U.K.
- 3Chiltern Diabetes Centre, Wycombe Hospital, High Wycombe, Buckinghamshire, U.K.
Abstract
OBJECTIVE—HNF-1α gene mutations (MODY3) present with marked hyperglycemia in lean young adults and may, therefore, be mistaken for type 1 diabetes, with implications for individual treatment and risk of diabetes in other family members. We examined the prevalence of HNF-1α mutations in families with three generations of diabetes identified in a population-based study of childhood diabetes, representing a subpopulation in which misclassification was likely.
RESEARCH DESIGN AND METHODS—In a study population of 1,470 families, 36 families (2.4%) with three affected generations were identified. In the 18 families in whom DNA samples were available, islet autoantibody testing, HLA class II genotyping, and HNF-1α sequencing were performed.
RESULTS—At least one islet autoantibody was found in 13 of 14 probands, and diabetes-associated HLA class II haplotypes were found in 17 of 18. One proband, who had no islet autoantibodies and was homozygous for the protective HLA haplotype DRB1*02-DQB1*0602, had a novel HNF-1α heterozygous nonsense mutation (R54X). This mutation cosegregated with diabetes in the family. The proband, his brother, mother, and maternal grandmother were diagnosed with type 1 diabetes aged 14–18 years and treated with insulin (0.39–0.74 units/kg) from diagnosis. The mother has since been successfully transferred to sulfonylurea treatment.
CONCLUSIONS—Family history alone is of limited value in identification of individuals with HNF-1α mutations, and we propose a stepwise approach that restricts sequencing of the HNF-1α gene to those with a family history of diabetes who also test negative for islet autoantibodies.
Footnotes
-
Address correspondence and reprint requests to Paul Lambert, Diabetes and Metabolism, Medical School Unit, Southmead Hospital, Bristol, BS10 5NB, U.K. E-mail: a.p.Lambert{at}bristol.ac.uk.
Received for publication 29 July 2002 and accepted in revised form 5 November 2002.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
- DIABETES CARE














